Trial Results Support Transition into Late-Stage Development with Program Expected to be Phase 2b/3-ready in H2 2026 BERLIN, GERMANY, January 29, 2026 – OMEICOS, a clinical-stage biopharmaceutical ...
Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.
BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.
When a biotech company announces positive Phase 3 trial results or receives FDA approval, the market reaction is often immediate and substantial. This is not just speculation. These milestones ...
The RansomHouse ransomware-as-a-service (RaaS) has recently upgraded its encryptor, switching from a relatively simple single-phase linear technique to a more complex, multi-layered method. In ...
Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.
Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile, ...
(RTTNews) - Shares of SELLAS Life Sciences Group Inc. (SLS) are up nearly 7% at $1.86 in premarket trading, following promising clinical data from its ongoing Phase 2 study of SLS009 in ...
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) released topline data on Wednesday from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with ...
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results